odevixibat Albireo Announces U.S. FDA Acceptance of New Drug Application for Odevixibat BOSTON, Jan. 25, 2021 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
